Nadina Erill ¹, Anna Colomer ^1, Míriam Gorriz ^1,2, Naim Hannaoui ³, Ruth Román ¹, Maria Conangla ², Josep M Banús ³, Carlos Cordon-Cardo ⁴, Xavier Puig ^1,2.

¹BIOPAT, Grup Assistència, Barcelona, Spain; ²HISTOPAT Laboratoris, Barcelona, Spain; ³Institut Català d’Urologia i Nefrologia, ICUN; Barcelona, Spain; and ⁴Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA.

Bladder tumors have a high recurrence rate, so treated patients are followed for detection of potential new lesions. Cystoscopy and cytology have been the standard […]

N.Erill ^1, A.Colomer ^1, C Pubill ², N. Hannaoui ³, R. Román ^1, M.Conangla ², JM. Banús ³, C. Cordón ¹, X. Puig ^1,2.

¹BIOPAT, Grup Assistència; ²HISTOPAT Laboratoris, ³Institut Català d’Urologia i Nefrologia, ICUN; Barcelona.

El carcinoma urotelial de bufeta és un dels tumors malignes més freqüents al nostre entorn. S’associa a una elevada taxa de recurrència, al voltant d’un 80% dels casos, i fins a un 30% pot evolucionar cap a carcinoma invasiu. Actualment, tant el diagnòstic com el seguiment […]

Erill N ¹, Colomer A ¹, Verdú M ², Román R ^1, Condom E ^2, Hannaoui N ^3, Banús JM ^3, Cordón-Cardó C ⁴, and Puig X ^1,2.

¹BIOPAT, Grup Assistència, Barcelona; ²HISTOPAT Laboratoris, Barcelona; ³ICUN, Barcelona; and ⁴Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Altered p53 status is a frequent event in bladder cancer and reported to have prognostic significance. We studied the TP53gene and its product in 76 patients affected with urinary bladder carcinomas by immunohistochemistry (mAb DO-7), […]